Tag Archives: DNDN

Healthcare Sector Recap: Agilent Technologies (NYSE:A), Athersys (NASDAQ:ATHX) – A, ATHX, OPXA, QCOR, DNDN, UNIS

Posted on May 15, 2013 by Thomas Vedder

Investors responded positively to the healthcare stocks on Tuesday. Key movement were observed in Questcor Pharmaceuticals Inc (NASDAQ:QCOR) and Dendreon Corporation (NASDAQ:DNDN) on percentage gainers side while Unilife Corp (NASDAQ:UNIS) was prominent stock on percentage decliner side.

Agilent Technologies Inc …

Posted in Healthcare, Latest Headlines | Tagged A, Agilent Technologies, Athersys, ATHX, Dendreon, DNDN, NASDAQ:ATHX, NASDAQ:DNDN, NASDAQ:OPXA, NASDAQ:QCOR, NASDAQ:UNIS, NYSE:A, Opexa Therapeutics, OPXA, QCOR, Questcor Pharmaceuticals, Unilife, UNIS | Comments Off

Quick News Overview of Healthcare Sector: Allscripts Healthcare (NASDAQ:MDRX), Dendreon (NASDAQ:DNDN) – MDRX, DNDN, CLSN, AFFY, DNDN, DCTH

Posted on May 10, 2013 by Thomas Vedder

Healthcare sector finished negatively on Thursday’s trading session and sector moved down -0.12%. If we consider key percentage decliners of this sector so Affymax, Inc (NASDAQ:AFFY) was major percentage gainer while key percentage decliners were Dendreon Corporation (NASDAQ:DNDN) and Delcath …

Posted in Healthcare, Latest Headlines | Tagged AFFY, Affymax, Allscripts Healthcare, Celsion, CLSN, DCTH, Delcath, Dendreon, DNDN, MDRX, NASDAQ:AFFY, NASDAQ:CLSN, NASDAQ:DCTH, NASDAQ:DNDN, NASDAQ:MDRX | Comments Off

Dendreon (NASDAQ:DNDN) Swings to Loss in Fiscal Q4; Stock Tumbles – DNDN, MDVN, PPHM, NLNK

Posted on February 26, 2013 by Thomas Vedder

Dendreon Corporation (NASDAQ:DNDN) on Monday announced a quarterly loss evaluated against a profit in previous year as revenue tumbled and restructuring expenses weighed on the biotechnology corporation.

The Seattle, Washington based company net loss was $38.7 million or 26 cents …

Posted in Healthcare, Latest Headlines | Tagged Dendreon, DNDN, MDVN, Medivation, NASDAQ:DNDN, NASDAQ:MDVN, NASDAQ:NLNK, NASDAQ:PPHM, NewLink Genetics, NLNK, Peregrine Pharmaceuticals, PPHM | Comments Off

Coventry Health Care (NYSE:CVH) Q4 Profit Outshines Wall Street Forecasts But Revenue Misses Estimates – CVH, AET, UNH, DNDN, CLDX, CLSN, PFE, BSX, ELN

Posted on February 6, 2013 by Geoff Noir

The Bethesda, Maryland-based Coventry Health Care, Inc (NYSE:CVH), which is being purchased by health insurer Aetna Inc (NYSE:AET), announced a profit for fiscal Q4 that hiked from previous year, showing strong operating margins amid lower costs and revenue expansion.

Managed …

Posted in Healthcare, Latest Headlines | Tagged AET, Aetna, Boston Scientific, BSX, Celldex Therapeutics, Celsion, CLDX, CLSN, Coventry Health Care, CVH, Dendreon, DNDN, Elan Corporation, ELN, NASDAQ:CLDX, NASDAQ:CLSN, NASDAQ:DNDN, NYSE:AET, NYSE:BSX, NYSE:CVH, NYSE:ELN, NYSE:PFE, NYSE:UNH, PFE, Pfizer, UNH, UnitedHealth | Comments Off

FTC New Topic of Scrutiny; Herbalife (NYSE:HLF) – DNDN, AMRN, ABBV, TEVA, BMY, CLS, HLF, BIDU, SBUX

Posted on February 4, 2013 by Thomas Vedder

On Monday, Herbalife (NYSE:HLF) the nutritional products distributor, is under investigation by the Federal Trade Commission, as per reported to the New York Post.

The report mentioned that the FTC has got 192 complaints against the company in the past …

Posted in Healthcare, Latest Headlines | Tagged ABBV, AbbVie, Amarin Corporation, AMRN, Baidu, BIDU, BMY, Bristol-Myers Squibb, Celsion, CLS, Dendreon, DNDN, Herbalife, HLF, NASDAQ:AMRN, NASDAQ:BIDU, NASDAQ:CLS, NASDAQ:DNDN, NASDAQ:SBUX, NYSE:ABBV, NYSE:BMY, NYSE:HLF, NYSE:TEVA, SBUX, Starbucks, TEVA, Teva Pharmaceutical Industries | Comments Off

Amgen Inc. (NASDAQ:AMGN) Declares Optimistic Results of Colorectal Cancer – AMGN, UNH, DNDN, GNBT, BSX, BMY, HLF, JNJ, NVS

Posted on January 28, 2013 by Thomas Vedder

Amgen Inc. (NASDAQ:AMGN) announced that results from a late-stage study of its low white blood cell therapy Neulasta for patients with colorectal cancer were optimistic.

In a study assessing Neulasta in 845 patients getting chemotherapy therapies for colorectal cancer, the …

Posted in Healthcare, Latest Headlines | Tagged Amgen, AMGN, BMY, Boston Scientific, Bristol-Myers Squibb, BSX, Dendreon, DNDN, Generex Biotechnology, GNBT, Herbalife, HLF, JNJ, Johnson & Johnson, NASDAQ:AMGN, NASDAQ:DNDN, Novartis, NVS, NYSE:BMY, NYSE:BSX, NYSE:HLF, NYSE:JNJ, NYSE:NVS, NYSE:UNH, OTC:GNBT, UNH, UnitedHealth | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.